{
    "clinical_study": {
        "@rank": "11861", 
        "brief_summary": {
            "textblock": "RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells.\n      Combining radiofrequency ablation with surgery may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with\n      surgery in treating patients who have stage I or stage II non-small cell lung cancer."
        }, 
        "brief_title": "Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in\n           patients with resectable non-small cell lung cancer.\n\n        -  Determine the treatment-related toxicity in patients treated with this therapy.\n\n        -  Determine the dimensions of the RFA lesion produced by the ablation procedure in these\n           patients.\n\n      OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes\n      for each tumor immediately followed by tumor resection.\n\n      PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of malignant non-small cell lung cancer (NSCLC)\n\n               -  Intraoperative needle biopsy confirmation allowed\n\n          -  Resectable disease (stage I or II)\n\n          -  All tissue to be treated by radiofrequency tumor ablation must be completely\n             contained within boundaries of planned lung resection\n\n          -  Medically fit to undergo lung resection\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Over 18\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  Not specified\n\n        Renal:\n\n          -  Not specified\n\n        Other:\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior or concurrent biologic therapy\n\n        Chemotherapy:\n\n          -  No prior or concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  No prior or concurrent endocrine therapy\n\n        Radiotherapy:\n\n          -  No prior or concurrent radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No other prior therapy for NSCLC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00039507", 
            "org_study_id": "CDR0000069389", 
            "secondary_id": [
                "P30CA006927", 
                "FCCC-02007", 
                "NCI-G02-2079"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "radiofrequency ablation", 
                "intervention_type": "Procedure"
            }
        ], 
        "keyword": [
            "stage I non-small cell lung cancer", 
            "stage II non-small cell lung cancer"
        ], 
        "lastchanged_date": "February 11, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FCCC-02007"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19111"
                }, 
                "name": "Fox Chase Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer", 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Walter J. Scott, MD, FACS", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00039507"
        }, 
        "source": "Fox Chase Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fox Chase Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2010"
    }, 
    "geocoordinates": {
        "Fox Chase Cancer Center": "39.952 -75.164"
    }
}